PMID- 23179639
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20211021
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Dec
TI  - Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.
PG  - 1060-9
LID - 10.1007/s10147-012-0497-2 [doi]
AB  - BACKGROUND: Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, has 
      demonstrated survival benefit in patients with metastatic renal cell carcinoma 
      (mRCC); however, significant adverse events (AEs) have been associated with its 
      use. The significant variation in the reported incidences of AEs has prompted 
      this meta-analysis to quantify the risk and explore associated predictors. 
      METHODS: According to predefined selection criteria, a literature search 
      identified 12 studies that were included in the analyses. RESULTS: The 
      meta-analysis included 5,658 patients; 66 % patients had prior systemic therapy 
      whereas the remaining patients (34 %) received sunitinib in the first-line 
      setting. For any grade toxicity, skin rash, fatigue, diarrhea, and mucositis were 
      the most frequently encountered events (81, 52, 45, and 33 %, respectively). 
      Anemia, neutropenia, or thrombocytopenia of any grade occurred in more than 
      one-third of patients, although grades 3 or 4 were less common. Any grade raised 
      by liver enzymes or serum creatinine occurred in 40 and 44 % of patients, 
      respectively. Meta-regression analyses showed that study size was inversely 
      related to the risk of experiencing fatigue, diarrhea, mucositis, anemia, and 
      thrombocytopenia. In particular, the incidence of AEs was higher when sunitinib 
      was used in pretreated versus naive patients; however, there was no significant 
      difference between the two groups concerning the incidence of laboratory 
      abnormalities. We addressed the limitations of reporting AEs in clinical studies. 
      CONCLUSIONS: The present meta-analysis quantified sunitinib-associated AEs. The 
      derived estimates would be similar to that to be expected from the use of 
      sunitinib in community practice in unselected patients with metastatic renal cell 
      carcinoma (mRCC).
FAU - Ibrahim, Ezzeldin M
AU  - Ibrahim EM
AD  - Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah, 
      21451, Kingdom of Saudi Arabia, ezzibrahim@imc.med.sa.
FAU - Kazkaz, Ghieth A
AU  - Kazkaz GA
FAU - Abouelkhair, Khaled M
AU  - Abouelkhair KM
FAU - Bayer, Ali M
AU  - Bayer AM
FAU - Elmasri, Osama A
AU  - Elmasri OA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20121121
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Drug-Related Side Effects and Adverse Reactions/classification/*pathology
MH  - Humans
MH  - Indoles/administration & dosage/*adverse effects
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Pyrroles/administration & dosage/*adverse effects
MH  - Sunitinib
EDAT- 2012/11/28 06:00
MHDA- 2014/08/19 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/09/19 00:00 [received]
PHST- 2012/10/28 00:00 [accepted]
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - 10.1007/s10147-012-0497-2 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2013 Dec;18(6):1060-9. doi: 10.1007/s10147-012-0497-2. Epub 
      2012 Nov 21.